Lumos Pharma, Inc.
LUMODelisted Dec 12, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001126234
Lumos Pharma, Inc. was delisted on Dec 12, 2024; its insiders filed their last Form 4 on Dec 13, 2024; 29 institutions reported holding it in 13F filings for Q3 2024, worth $8.08M in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Lumos Pharma, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Lumos Pharma, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Zoth Lota S. | Director | 0 | Dec 13, 2024 | 0 |
| Hawkins Richard J | Chief Executive Officer | 0Indirect | Dec 13, 2024 | 0 |
| Raffin Thomas A. | Director | 0 | Dec 13, 2024 | 0 |
| Lalande Kevin M. | Director | 0Indirect | Dec 13, 2024 | 0 |
| McCracken Joseph S | Director | 0 | Dec 13, 2024 | 0 |
| McKew John C. | Chief Scientific Officer | 0 | Dec 13, 2024 | 0 |
| Schuchart Aaron | Chief Business Officer | 0 | Dec 13, 2024 | 0 |
| Johnson Chad Allen | Director | 0 | Dec 13, 2024 | 0 |
| Lawley Lori D | Chief Financial Officer | 0 | Dec 13, 2024 | 0 |
| Powers Bradley J | General Counsel | 0Indirect | Dec 13, 2024 | 0 |
| van Es-Johansson An | Director | 0 | Dec 13, 2024 | 0 |
| Pitukcheewanont Pisit Duke | Chief Medical Officer | 0 | Dec 13, 2024 | 0 |
| Karpf David B | Chief Medical Officer | 8,294 | Feb 3, 2023 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 6, 2024 (view filing) | Aug 6 | Same day | McKew John C.Chief Scientific Officer | SSale | −3.41K | $1.89 | −$6.44K | −21.2%12.7K after | 10b5-1 |
| Apr 3, 2024 (view filing) | Apr 3 | Same day | McKew John C.Chief Scientific Officer | SSale | −2.21K | $2.78 | −$6.15K | −11.4%17.2K after | 10b5-1 |
| Feb 7, 2024 (view filing) | Feb 6 | 1 day | McKew John C.Chief Scientific Officer | SSale | −438 | $3.03 | −$1.33K | −2.3%18.4K after | 10b5-1 |
| Aug 3, 2023 (view filing) | Aug 2 | 1 day | McKew John C.Chief Scientific Officer | SSale | −3.41K | $3.21 | −$10.9K | −15.4%18.7K after | 10b5-1 |
| Apr 4, 2023 (view filing) | Apr 4 | Same day | McKew John C.Chief Scientific Officer | SSale | −2.21K | $3.27 | −$7.24K | −8.7%23.2K after | 10b5-1 |
| Feb 3, 2023 (view filing) | Feb 2 | 1 day | McKew John C.Chief Scientific Officer | SSale | −439 | $3.53 | −$1.55K | −1.6%26.5K after | |
| Nov 18, 2022 (view filing) | Nov 16 | 2 days | McCracken Joseph SDirector | PPurchase | +4.00K | $5.03 | +$20.1K | +34.1%15.7K after | |
| Sep 23, 2022 (view filing) | Sep 21-23 | 2 days | Hawkins Richard JChief Executive Officer | PPurchase | +2.42K | $8.84 | +$21.4K | +118.3%4.47K after | 2 lots |
| Sep 21, 2022 (view filing) | Sep 19-20 | 2 days | Hawkins Richard JChief Executive Officer | PPurchase | +2.05K | $8.72 | +$17.9K | New position2.05K after | 2 lots |
| Aug 26, 2022 (view filing) | Aug 25 | 1 day | Raffin Thomas A.Director | PPurchase | +1.15K | $8.46 | +$9.73K | +13.9%9.41K after | |
| Aug 26, 2022 (view filing) | Aug 25 | 1 day | McCracken Joseph SDirector | PPurchase | +3.17K | $8.60 | +$27.3K | +37.1%11.7K after | |
| Aug 3, 2022 (view filing) | Aug 2 | 1 day | McKew John C.Chief Scientific Officer | SSale | −3.41K | $8.11 | −$27.6K | −12.2%24.6K after | |
| Jun 7, 2022 (view filing) | Jun 6 | 1 day | McKew John C.Chief Scientific Officer | SSale | −169 | $7.62 | −$1.29K | −0.6%29.1K after | |
| Apr 5, 2022 (view filing) | Apr 5 | Same day | McKew John C.Chief Scientific Officer | SSale | −2.21K | $8.32 | −$18.4K | −7.0%29.3K after | |
| Sep 10, 2021 (view filing) | Sep 8 | 2 days | McKew John C.Chief Scientific Officer | SSale | −2.21K | $11.30 | −$25.0K | −6.7%31.0K after | |
| Sep 10, 2021 (view filing) | Sep 8 | 2 days | Lalande Kevin M.Director | PPurchase | +10.0K | $11.21 | +$112.1K | +1.4%730.4K after | |
| Sep 7, 2021 (view filing) | Sep 2-7 | 5 days | Lalande Kevin M.Director | PPurchase | +24.4K | $11.22 | +$273.8K | +3.5%720.4K after | 3 lots |
| Sep 1, 2021 (view filing) | Aug 30-Sep 1 | 2 days | Lalande Kevin M.Director | PPurchase | +19.2K | $10.66 | +$204.8K | +2.8%696.0K after | 3 lots |
| Aug 27, 2021 (view filing) | Aug 25-27 | 2 days | Lalande Kevin M.Director | PPurchase | +26.1K | $10.04 | +$261.8K | +4.0%677.8K after | 3 lots |
| Aug 24, 2021 (view filing) | Aug 20-24 | 4 days | Lalande Kevin M.Director | PPurchase | +84.3K | $9.20 | +$775.4K | +14.8%651.8K after | 3 lots |
| Aug 19, 2021 (view filing) | Aug 17-19 | 2 days | Lalande Kevin M.Director | PPurchase | +64.9K | $8.58 | +$556.6K | +12.9%567.5K after | 3 lots |
| Aug 16, 2021 (view filing) | Aug 12-16 | 4 days | Lalande Kevin M.Director | PPurchase | +93.0K | $7.79 | +$724.5K | +22.7%502.6K after | 3 lots |
| Aug 13, 2021 (view filing) | Aug 11-12 | 2 days | Schuchart AaronChief Business Officer | PPurchase | +2.00K | $7.41 | +$14.8K | +192.9%3.04K after | 2 lots |
| Aug 13, 2021 (view filing) | Aug 11 | 2 days | McCracken Joseph SDirector | PPurchase | +7.47K | $7.55 | +$56.4K | +694.7%8.55K after |